ImPact enters partnership for pathologic myopia therapy development
14 Aug 2023
Phase 3Drug Approval
Preview
Source: Pharmaceutical Technology
Pathologic myopia, or myopic macular degeneration, is a severe eye disease. Credit: Serafino Mozzo / Shutterstock.com.
Israeli biotech organisation ImPact Biotech has entered a research partnership with Maastricht University in the Netherlands to develop a therapy for arresting the progression of pathologic myopia or myopic macular degeneration (MMD), a severe eye disease.
The organisation will work with two researchers from the university, associate professor Dr Mor Dickman and MERLN Institute associate professor Dr Vanessa LaPointe.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Radiprodil in Neurodegenerative Diseases GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Spebrutinib Besylate in Follicular Lymphoma GlobalData
View allCompanies IntelligenceMaastricht UniversityImpact BioTech LtdView all
The parties will leverage the Padeliporfin vascular targeted photodynamic (VTP) therapy platform of ImPact for developing the treatment.
Padeliporfin has received the European Medicines Agency’s approval for usage in low-risk prostate cancer patients.
It is currently being evaluated in a Phase III clinical trial for treating low-grade upper tract urothelial carcinoma.
The organisation also plans to commence further studies of Padeliporfin in patients with non-small cell lung cancer and pancreatic cancer.
ImPact Biotech Research and Development global head Dr David Perry stated: “We look forward to collaborating with Maastricht University’s Drs LaPointe and Dickman on this important research collaboration to address the huge unmet medical need in progressive myopia while leveraging our Padeliporfin VTP technology to help patients afflicted with this highly debilitating condition.
“Initial results with our Padeliporfin approach are very encouraging and we are looking forward to progressing it rapidly towards clinical research by growing our understanding of the disease and the potential interventions to change its course with the contribution of this collaboration.”
The organisation is also partnering with research institutes and specialists in associated areas to analyse its platform’s potential to treat pathological myopia.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.